Abediterol

Abediterol (INN; development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD), but it has never been marketed.

History
Abediterol was under development by the Spanish pharmaceutical company Almirall and reached Phase II clinical trials, but was discontinued in 2021. Its coformulation with mometasone furoate also progressed to Phase II clinical trials, but was discontinued in 2019.

Mechanism of action
Abediterol acts as a dual β2 adrenergic agonist and muscarinic antagonist and is classified as an ultra-long-acting β2 agonist (ultra-LABA).